Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug classes in Europe since 2011. Although laser photocoagulation has long been the standard of care for patients with the most advanced stages of DR, recent clinical trial results suggest that intravitreal pharmacotherapy injections may be effective treatment for this broader patient population as well. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the United States and EU5 markets for DR and DME. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment | EU detailed, expanded analysis offers a snapshot of how ophthalmologists in the EU5 are currently treating DR and DME patients, with a particular focus on use of intravitreal vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid implants, as well as insight into the factors driving such prescribing habits.
- Diabetic Macular Edema / Diabetic Retinopathy - Current Treatment - Detailed, Expanded Analysis (EU)
Author(s): Emma McFadden, PhD; Margaret M. Weigel
Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy.
Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.
Margaret Weigel, M.B.A., is a Business Insights Analyst on the CNS/Ophthalmology Disorders team at Decision Resources Group. Her specialties are diabetic retinopathy/diabetic macular edema, postoperative pain, and multiple sclerosis; she has authored numerous primary and secondary market research products on these indications. Ms. Weigel obtained her B.A. from Washington and Lee University, where she studied psychology and conducted research in the neuroscience department, and her M.B.A. in pharmaceutical and healthcare business from the University of the Sciences in Philadelphia.